Back to Results
First PageMeta Content
Cyclopropanes / Organofluorides / Chemistry / Organic chemistry / Cabozantinib / Exelixis / Mesothelioma / Foretinib / Mapatumumab / Tyrosine kinase inhibitors / Medicine / Quinolines


Document Date: 2010-10-19 13:01:07

Open Document

File Size: 42,16 KB

Share Result on Facebook

City

ATLANTA / /

Company

Helsinn Healthcare S.A. / Exelixis Inc. / GlaxoSmithKline / Bristol-Myers Squibb Company / /

Event

FDA Phase / Business Partnership / /

IndustryTerm

biotechnology / cancer therapies / treatment for renal disease / pharmaceutical / /

MedicalCondition

tumor / currently approved cancer / serious diseases / bile duct tumor / cancer / tumors / disease / NSCLC / metabolic and cardiovascular disorders / preclinical tumor / solid tumors / adenoid cystic carcinoma / hematologic malignancies / human tumors / breast / lung / colon and prostate cancer / prolonged stable disease / mesothelioma / diseases / non-small cell lung cancer / adrenocortical carcinoma / renal disease / pulmonary embolism / diarrhea / chordoma / head and neck cancer / /

MedicalTreatment

cancer therapies / /

Organization

American Society of Clinical Oncology / /

Person

George A. Scangos / Alex Adjei / /

Position

author / president and chief executive officer / Professor of Oncology / /

Product

XL784 / XL647 / HER2 / XL999 / /

Technology

biotechnology / /

URL

http /

SocialTag